Journal of Cellular and Molecular Pharmacology
Open Access

Drug transporters; Cellular gateways; Therapeutic delivery; Pharmacokinetics; Drug absorption; Drug distribution; Drug metabolism; Drug-drug interactions; Targeted drug delivery

Introduction

In the intricate realm of human biology, the journey of a therapeutic drug from its point of administration to its target destination within the body is a remarkable feat of precision and complexity. Central to this journey are the cellular gatekeepers known as drug transporters, a class of specialized proteins that orchestrate the intricate dance of molecules crossing cellular membranes. These molecular sentinels hold the key to unlocking the potential of medical treatments, shaping the efficacy and safety of therapeutic delivery.

Imagine a bustling metropolis, where roads, highways, and pathways connect every corner. In a similar vein, the human body consists of a vast network of cells, each with its own function and domain. However, just as a city relies on controlled points of entry and exit to maintain order, cells utilize drug transporters to regulate the flow of substances in and out of their domains. This control is not limited to mundane molecules; it extends to therapeutic drugs that hold the promise of treating ailments and improving lives [1].

In this exploration, we embark on a journey through the cellular gateways that are drug transporters. We will delve into their pivotal role in the absorption, distribution, metabolism, and excretion of medications. Our voyage will take us into the intricacies of these transporter proteins, revealing how they navigate the complex terrain of biological barriers, such as the blood-brain barrier and placental barrier, influencing the fate of drugs in various compartments of the body [2].

Unveiling the cellular gatekeepers

Drug transporters are specialized proteins embedded within cell membranes that facilitate the movement of molecules in and out of cells. These transporters are categorized into two major families: ATP-binding cassette transporters and solute carrier transporters. ABC transporters use energy derived from ATP hydrolysis to actively pump substances across cell membranes, while SLC transporters utilize passive diffusion or facilitated transport mechanisms.

The discovery of drug transporters and their role in pharmacokinetics revolutionized our understanding of drug metabolism and efficacy. Early drug development focused primarily on the interaction between drugs and their target molecules within cells. However, it became evident that drug transporters could significantly impact a drug’s bioavailability and distribution, influencing its overall therapeutic effect.

Impact on therapeutic delivery

Drug transporters can significantly influence the pharmacokinetics and pharmacodynamics of various medications. Their role is particularly crucial in tissues with complex barriers, such as the blood-brain barrier and the blood-placental barrier, where they regulate the entry of drugs into specific compartments. For instance, the permeability glycoprotein, encoded by the ABCB1 gene, is a wellknown transporter responsible for limiting the entry of drugs into the central nervous system, thus affecting the treatment of brain disorders.

The interplay between drug transporters and therapeutic delivery becomes especially relevant when considering drug-drug interactions. Co-administered drugs may compete for the same transporter, potentially leading to altered absorption and distribution. This phenomenon can result in reduced efficacy or increased toxicity of one or both drugs. Pharmaceutical companies and researchers must consider transporter interactions during drug development to ensure safe and effective therapeutic regimens.

Tailoring therapies through transporter knowledge

The field of pharmacogenomics seeks to individualize medical treatments based on a person’s genetic makeup. Drug transporter genes can harbor variations, known as single nucleotide polymorphisms that influence transporter function. These genetic differences can lead to variations in drug response, efficacy, and toxicity among individuals.

Pharmacogenomic studies have revealed significant associations between transporter gene polymorphisms and drug responses. For instance, certain genetic variations in the gene encoding organic anion transporter 1B1 have been linked to altered statin metabolism and an increased risk of statin-induced myopathy. By identifying these genetic variations, clinicians can make informed decisions about drug selection, dosage adjustments, and personalized treatment plans.

Strategies for optimizing drug delivery

The intricate role of drug transporters in therapeutic delivery has prompted researchers to develop strategies aimed at modulating their activity. Prodrug design involves chemically modifying a drug to make it a substrate for a specific transporter. This approach allows for targeted delivery of the active drug to its intended site of action. Additionally, researchers are exploring the potential of drug transporter inhibitors and inducers to enhance drug efficacy. By inhibiting transporters that limit drug distribution, medications can reach their intended targets more effectively [3-6].

Discussion

Cellular gateways and drug transporters:

Cellular gateways refer to the various mechanisms that control the entry and exit of molecules, including drugs, into and out of cells. These gateways play a crucial role in regulating the movement of substances across cellular membranes, ensuring that the right molecules enter and exit cells while maintaining the internal environment’s stability.

Drug transporters are specialized proteins found on cell membranes that facilitate the movement of drugs across these barriers. They are divided into two main categories: influx transporters, which facilitate drug entry into cells, and efflux transporters, which pump drugs out of cells. Examples of drug transporters include P-glycoprotein, organic anion transporting polypeptides, and organic cation transporters. These transporters can significantly influence drug absorption, distribution, and elimination, impacting the overall pharmacokinetics of a drug.

Impact on therapeutic delivery

Drug transporters have a significant impact on therapeutic delivery. Here are some key points to consider in this discussion:

Bioavailability: The expression and activity of drug transporters can influence a drug’s bioavailability. High expression of efflux transporters like P-gp in the gastrointestinal tract can lead to decreased absorption of orally administered drugs, limiting their effectiveness.

Tissue distribution: Drug transporters play a role in determining which tissues drugs will accumulate in. For instance, transporters in the blood-brain barrier can restrict the entry of drugs into the brain, posing challenges for treating central nervous system disorders.

Drug-drug interactions: Many drugs are substrates or inhibitors of transporters. Co-administration of drugs that interact with the same transporter can lead to altered pharmacokinetics and potential drugdrug interactions. This can impact the efficacy and safety of therapeutic regimens.

Efflux pump resistance: Overexpression of efflux transporters, particularly P-gp, in cancer cells can lead to multidrug resistance. This phenomenon reduces the effectiveness of chemotherapy by pumping out anticancer drugs, rendering them less effective.

Targeted delivery: Understanding the expression patterns of transporters can enable the design of targeted drug delivery strategies.

Utilizing transporters that are overexpressed in certain tissues or cells can enhance drug delivery to specific sites.

Future directions

Research in this field is ongoing and aims to develop a deeper understanding of drug transporter biology. This includes studying transporter regulation, tissue-specific expression, and the impact of genetic variations on transporter function. Additionally, efforts are being made to harness transporter knowledge for improved drug design and personalized medicine, where treatment plans could be tailored based on an individual’s transporter profile [7-10].

Conclusion

The study of drug transporters has shed light on the challenges and opportunities in therapeutic delivery. Researchers and pharmaceutical companies have recognized the importance of considering transportermediated interactions during drug development. Understanding how these transporters influence the pharmacokinetics and pharmacodynamics of drugs allows for more informed decisions in optimizing drug formulations, dosing regimens, and targeting specific tissues or cells. The development of transporter-based drug delivery strategies has gained momentum in recent years. By exploiting the selective expression of certain transporters in specific tissues, researchers have been able to enhance drug delivery to desired sites while minimizing off-target effects. This has paved the way for personalized medicine approaches where drug regimens can be tailored based on an individual’s transporter expression profile.

Conflict of Interest

None

Acknowledgement

None

1. Alghannam AF, Ghaith MM, Alhussain MH (2021) Regulation of energy substrate metabolism in endurance exercise. Int J Environ Res Public Health 18:4963.

Indexed at, Google Scholar, Crossref

2. Rigoulet M, Bouchez CL, Paumard P, Ransac S, Cuvellier S, et al. (2020) Cell energy metabolism: an update. Biochim Biophys Acta Bioenerg 1861:148276.

Indexed at, Google Scholar, Crossref

3. Den Besten G, Van Eunen K, Groen AK, Venema K, Reijngoud DJ, et al. (2013) The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res 54:2325-2340.

Indexed at, Google Scholar, Crossref

4. Sahuri-Arisoylu M, Brody LP, Parkinson JR, Parkes H, Navaratnam N, et al. (2016) Reprogramming of hepatic fat accumulation and 'browning' of adipose tissue by the short-chain fatty acid acetate. Int J Obes (London) 40:955-963.

Indexed at, Google Scholar, Crossref

5. Scheithauer TP, Rampanelli E, Nieuwdorp M, Vallance BA, Verchere CB, et al. (2016) Gut Microbiota as a Trigger for Metabolic Inflammation in Obesity and Type 2 Diabetes. Frontiers in immunology 2546.

Indexed at, Google Scholar, Crossref

6. Amabebe E, Robert FO, Agbalalah T, Orubu ES (2020) Microbial dysbiosis-induced obesity: role of gut microbiota in homoeostasis of energy metabolism. Br J Nutr 123:1127-1137.

Indexed at, Google Scholar, Crossref

7. Vrieze A, Holleman F, Zoetendal EG, De Vos WM, Hoekstra JBL, et al. (2010) The environment within: how gut microbiota may influence metabolism and body composition. Diabetologia 53:606-613.

Indexed at, Google Scholar, Crossref

8. Singh RK, Chang HW, Yan D, Lee KM, Ucmak D, et al. (2017) Influence of diet on the gut microbiome and implications for human health. J Transl Med 15:1-7.

Indexed at, Google Scholar, Crossref

9. Boekhorst J, Venlet N, Procházková N, Hansen ML, Lieberoth CB, et al. (2022) Stool energy density is positively correlated to intestinal transit time and related to microbial enterotypes. Microbiome 10:223.

Indexed at, Google Scholar, Crossref

10. Ghosh TS, Gupta SS, Bhattacharya T, Yadav D, Barik A, et al. (2014) Gut microbiomes of indian children of varying nutritional status. PLoS ONE 9:e95547.

Indexed at, Google Scholar, Crossref